SOUTH SAN FRANCISCO, Calif., May 27, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received a letter on May 20, 2008, from the Nasdaq Stock Market, Inc., notifying the Company that its total stockholders' equity, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008, does not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing on The Nasdaq Global Market set forth in Marketplace Rule 4450(a)(3).
